> Detailanzeige

Merryman, Reid W.; Redd, Robert A.; Nishihori, Taiga; Chavez, Julio; Nieto, Yago; Darrah, Justin M.; Rao, Uttam; Byrne, Michael T.; Bond, David A.; Maddocks, Kami J.; Spinner, Michael A.; Advani, Ranjana H.; Ballard, Hatcher J.; Svoboda, Jakub; Singh, Anurag K.; McGuirk, Joseph P.; Modi, Dipenkumar; Ramchandren, Radhakrishnan; Romancik, Jason; Cohen, Jonathon B.; Frigault, Matthew J.; Chen, Yi-Bin; Serritella, Anthony V.; Kline, Justine; [...]

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
  • Beteiligte: Merryman, Reid W.; Redd, Robert A.; Nishihori, Taiga; Chavez, Julio; Nieto, Yago; Darrah, Justin M.; Rao, Uttam; Byrne, Michael T.; Bond, David A.; Maddocks, Kami J.; Spinner, Michael A.; Advani, Ranjana H.; Ballard, Hatcher J.; Svoboda, Jakub; Singh, Anurag K.; McGuirk, Joseph P.; Modi, Dipenkumar; Ramchandren, Radhakrishnan; Romancik, Jason; Cohen, Jonathon B.; Frigault, Matthew J.; Chen, Yi-Bin; Serritella, Anthony V.; Kline, Justine; [...]
  • Erschienen: American Society of Hematology, 2021
  • Erschienen in: Blood Advances
  • Sprache: Englisch
  • DOI: 10.1182/bloodadvances.2020003556
  • ISSN: 2473-9529; 2473-9537
  • Schlagwörter: Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:p>Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would result in acceptable outcomes among high-risk patients who progressed on or responded insufficiently to ≥1 salvage regimen, including chemorefractory patients who are traditionally considered poor ASCT candidates. We retrospectively identified 78 HL patients who underwent ASCT after receiving an anti-PD-1 mAb (alone or in combination) as third-line or later therapy across 22 centers. Chemorefractory disease was common, including 42 patients (54%) refractory to ≥2 consecutive systemic therapies immediately before anti-PD-1 treatment. Fifty-eight (74%) patients underwent ASCT after anti-PD-1 treatment, while 20 patients (26%) received additional therapy after PD-1 blockade and before ASCT. Patients received a median of 4 systemic therapies (range, 3-7) before ASCT, and 31 patients (41%) had a positive pre-ASCT positron emission tomography (PET) result. After a median post-ASCT follow-up of 19.6 months, the 18-month progression-free survival (PFS) and overall survival were 81% (95% CI, 69-89) and 96% (95% confidence interval [CI], 87-99), respectively. Favorable outcomes were observed for patients who were refractory to 2 consecutive therapies immediately before PD-1 blockade (18-month PFS, 78%), had a positive pre-ASCT PET (18-month PFS, 75%), or received ≥4 systemic therapies before ASCT (18-month PFS, 73%), while PD-1 nonresponders had inferior outcomes (18-month PFS, 51%). In this high-risk cohort, ASCT after anti-PD-1 therapy was associated with excellent outcomes, even among heavily pretreated, previously chemorefractory patients.</jats:p>
  • Zugangsstatus: Freier Zugang